Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
130M
-
Number of holders
-
277
-
Total shares
-
92.1M
-
Shares change
-
+4.76M
-
Total reported value, excl. options
-
$11.7B
-
Value change
-
+$613M
-
Put/Call ratio
-
0.78
-
Number of buys
-
167
-
Number of sells
-
-91
-
Price
-
$127.05
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY) as of Q4 2017
303 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - Common Stock as of Q4 2017.
ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY) has 277 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 92.1M shares
of 130M outstanding shares and own 70.75% of the company stock.
Largest 10 shareholders include FMR LLC (14.9M shares), PRICE T ROWE ASSOCIATES INC /MD/ (12.2M shares), WELLINGTON MANAGEMENT GROUP LLP (9.18M shares), DODGE & COX (8.23M shares), Vanguard Group Inc (7.26M shares), BlackRock Inc. (7.12M shares), BAILLIE GIFFORD & CO (3.61M shares), STATE STREET CORP (2M shares), UBS ASSET MANAGEMENT AMERICAS INC (1.39M shares), and Blue Ridge Capital, L.L.C. (1.34M shares).
This table shows the top 277 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.